The relationship between lung fibrosis, the epidermal growth factor receptor, and disease outcomes in COVID-19 pneumonia: a postmortem evaluation

Seyhan Us Dülger, Nazmi Mutlu, İlkay Ceylan, Erhan Özhan, Seyhan Us Dülger, Nazmi Mutlu, İlkay Ceylan, Erhan Özhan

Abstract

The aim of this study was to examine the relationship between the severity of fibrosis in lung tissue and epidermal growth factor receptor (EGFR) positivity in patients who died due to COVID-19 pneumonia, demographic characteristics, comorbidities, biochemical values, and treatments received. Fifty patients who died from COVID-19 pneumonia were included in the study. Demographic data for the patients, laboratory tests, thorax computerized tomography findings, comorbidities, length of stay in the intensive care unit (ICU), intubation times, and treatments given were noted. Postmortem Tru-cut lung biopsy was performed. EGFR positivity was examined and grouped as negative, mild, moderate, and severe. Data were analyzed statistically. EGFR involvement was negative in 11 (22%), mild in 20 (40%), moderate in 13 (26%), and severe in 6 (12%) patients. The mean C-reactive protein (CRP) values, D-dimer values, and mean length of stay in the ICU were found to be significantly different between the groups (p = 0.024; p = 0.003; p = 0.016, respectively). Methylprednisolone dose and the presence of comorbidity did not differ significantly in EGFR involvement (p = 0.79; p = 0.98, respectively). CRP and D-dimer values can be used as a guide to assess the severity of pulmonary fibrosis that develops in severe COVID-19 pneumonia patients. The dose of methylprednisolone used does not make a significant difference in the severity of fibrosis.Trail registration: Clinical Trials.gov identifier date and number 01/13/2022 NCT05290441.

Keywords: A typical pneumonias; Biopsy; Epidermal growth factor receptor; Postmortem diagnoses; Pulmonary fibrosis.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Figures

Fig. 1
Fig. 1
Sample image (× 400) of the staining results with the EGFR kits

References

    1. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al. Post mortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77:198–209. doi: 10.1111/his.14134.
    1. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Post grad Med J. 2021;97:312–320. doi: 10.1136/postgradmedj-2020-138577.
    1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–1349. doi: 10.1056/NEJM200005043421806.
    1. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage the role of oxygen, shock, and related factors: a review. Am J Pathol. 1976;85(1):209–287.
    1. Sauter JL, Baine MK, Butnor KJ, Buonocore DJ, Chang JC, Jungbluthet AA, et al. Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. Histopathology. 2020;77(6):915–925. doi: 10.1111/his.14201.
    1. Tannia SE, Fabrob AT, Albuquerquec A, Ferreirad EVM, Verrastroe CGY, Sawamuraf MVY, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med. 2021 doi: 10.1080/17476348.2021.1916472.
    1. Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020;27:3209–3225. doi: 10.1038/s41418-020-00633-7.
    1. Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Hindawi Pulm Med. 2020;2020(6175964):1–10. doi: 10.1155/2020/6175964.
    1. Hondermarck H, Bartlett NW, Nurcombe V. The role of growth factor receptors in viral infections: an opportunity for drug repurposing against emerging viral diseases such as COVID-19. FASEB BioAdv. 2020;2:296–303. doi: 10.1096/fba.2020-00015.
    1. Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review. Fedchenko and Reifenrath Diagnostic Pathology 2014, 9:221
    1. Bachofen M, Weibel ER. Alterations of the gas Exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis. 1977;116:589–615. doi: 10.1164/arrd.1977.116.4.589.
    1. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med. 1982;3:35–56. doi: 10.1016/S0272-5231(21)00143-X.
    1. Finigan JH, Downey GP, Kern JA. Human epidermal growth factor receptor signaling in acute lung injury. Am J Respir Cell Mol Biol. 2012;47:395–404. doi: 10.1165/rcmb.2012-0100TR.
    1. Martin C, Papazian L, Payan MJ, Saux P, Gouin F. Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome: a study in mechanically ventilated patients. Chest. 1995;107:196–200. doi: 10.1378/chest.107.1.196.
    1. Huang W, Qingxia W, Chen Z, Xiong Z, Wang K, Tian J, et al. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J Infect. 2021;82(2):e5–e7. doi: 10.1016/j.jinf.2020.09.027.
    1. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C- reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370. doi: 10.1016/j.jcv.2020.104370.
    1. Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. Prediction of the development of pulmonary fibrosis using serial thin-section ct and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol. 2020;21(6):746–755. doi: 10.3348/kjr.2020.0215.
    1. Ishikawa G, Acquah SO, Salvatore M, Padilla ML. Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease. Respir Med. 2017;128:78–84. doi: 10.1016/j.rmed.2017.05.009.
    1. Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L, et al. Chest CT score in COVID-19 patients: correlation with disease Severity and short-term prognosis. Eur Radiol. 2020;30(12):6808–6817. doi: 10.1007/s00330-020-07033-y.
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-n CoV lung injury. Lancet. 2020;395:473–475. doi: 10.1016/S0140-6736(20)30317-2.
    1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with corona virus disease 2019 pneumonia in Wuhan China. JAMA Intern Med. 2020;180(7):934–943. doi: 10.1001/jamainternmed.2020.0994.
    1. preliminary- results-about-dexamethasone-use-in-treating-critically-illcovid-19-patients.
    1. Chen Y, Li L. Influence of corticosteroid dose on viral shedding duration in patients with COVID-19. Clin Infect Dis. 2021;72(7):1298–1300. doi: 10.1093/cid/ciaa832.
    1. Ding M, Zhang Q, Li Q, Wu T, Huang Y, et al. Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19. Respir Med. 2020;167:105981. doi: 10.1016/j.rmed.2020.105981.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner